OBJECTIVE: Sustained antiretroviral therapy (ART)-mediated viral suppression restores responses to vaccination in HIV-1-infected individuals. As ART interruption occur frequently in resource-constrained settings, we studied their effects on the ability to mount humoral immune responses against a neoantigen. DESIGN: Treatment-naive HIV-1-infected individuals were treated with stavudine, lamuvidine and lopinavir/ritonovir. Individuals who maintained viral load less than 50 copies/ml and CD4 T-cell counts more than 450 cells/μl for 6 months received three doses of rabies vaccine, and were randomized to 72 weeks of continuous ART (arm 1) or sequential 2, 4 and 8-week ART interruptions (arm 2). An additional vaccine dose was administered at study end. METHODS: Neutralizing antibody titers to rabies virus were assessed in plasma with a rapid fluorescent focus-inhibiting test. RESULTS: The proportion of participants achieving protective (>0.5 IU/ml) antibody titer after vaccination was similar (arm 1=92%; arm 2=91%), but over time the cumulative proportion of observations with protective titer was greater in arm 1 than arm 2 (P=0.0177). From week 26 after vaccination, antibody titers were lower in arm 2 than arm 1, and volunteers in arm 2 lost protective antibody titers at a greater rate (P=0.0029). After boosting, 100% of arm 1 and 95% arm 2 volunteers achieved protective antibody titer. CONCLUSION: Our data indicate that individuals undergoing recurring ART interruption retain lower neutralizing antibody titers to a neoantigen, but maintain the ability to mount secondary responses upon boosting, suggesting that they might benefit from vaccine schedule intensification.
RCT Entities:
OBJECTIVE: Sustained antiretroviral therapy (ART)-mediated viral suppression restores responses to vaccination in HIV-1-infected individuals. As ART interruption occur frequently in resource-constrained settings, we studied their effects on the ability to mount humoral immune responses against a neoantigen. DESIGN: Treatment-naive HIV-1-infected individuals were treated with stavudine, lamuvidine and lopinavir/ritonovir. Individuals who maintained viral load less than 50 copies/ml and CD4 T-cell counts more than 450 cells/μl for 6 months received three doses of rabies vaccine, and were randomized to 72 weeks of continuous ART (arm 1) or sequential 2, 4 and 8-week ART interruptions (arm 2). An additional vaccine dose was administered at study end. METHODS: Neutralizing antibody titers to rabies virus were assessed in plasma with a rapid fluorescent focus-inhibiting test. RESULTS: The proportion of participants achieving protective (>0.5 IU/ml) antibody titer after vaccination was similar (arm 1=92%; arm 2=91%), but over time the cumulative proportion of observations with protective titer was greater in arm 1 than arm 2 (P=0.0177). From week 26 after vaccination, antibody titers were lower in arm 2 than arm 1, and volunteers in arm 2 lost protective antibody titers at a greater rate (P=0.0029). After boosting, 100% of arm 1 and 95% arm 2 volunteers achieved protective antibody titer. CONCLUSION: Our data indicate that individuals undergoing recurring ART interruption retain lower neutralizing antibody titers to a neoantigen, but maintain the ability to mount secondary responses upon boosting, suggesting that they might benefit from vaccine schedule intensification.
Authors: S Horster; R P Laubender; L Lehmeyer; D P Ankerst; J Eberle; R Reinert; M Imöhl; M van der Linden; B Schweiger; J R Bogner Journal: J Infect Date: 2010-09-25 Impact factor: 6.072
Authors: Edgar Turner Overton; Somnuek Sungkanuparph; William G Powderly; Warren Seyfried; Richard K Groger; Judith A Aberg Journal: Clin Infect Dis Date: 2005-08-22 Impact factor: 9.079
Authors: Rachel B Yoder; Winstone M Nyandiko; Rachel C Vreeman; Samwel O Ayaya; Peter O Gisore; Paula Braitstein; Sarah E Wiehe Journal: J Acquir Immune Defic Syndr Date: 2012-02-01 Impact factor: 3.731
Authors: Luc B S Gelinck; Cornelia M Jol-van der Zijde; Anja M Jansen-Hoogendijk; Daniëlle M C Brinkman; Jaap T van Dissel; Maarten J D van Tol; Frank P Kroon Journal: AIDS Date: 2009-11-27 Impact factor: 4.177
Authors: David Kuhrt; Seth A Faith; Amanda Leone; Mukta Rohankedkar; Donald L Sodora; Louis J Picker; Kelly Stefano Cole Journal: J Virol Date: 2009-12-23 Impact factor: 5.103
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245